氯沙坦联合阿托伐他汀治疗原发性高血压的疗效及对血浆高敏C反应蛋白、内皮素和一氧化氮水平的影响

Effect of losartan combined with atorvastatin in treatment of essential hypertension and its influence on the plasma high sensitive C reactive protein, endothelial factors, and levels of nitric oxide

目的 探讨氯沙坦联合阿托伐他汀治疗原发性高血压的临床疗效及对血浆高敏C反应蛋白（hs-CRP）、内皮素（ET）和一氧化氮（NO）水平的影响.方法 将84例原发性高血压患者采用数字表法随机分为两组,每组各42例,对照组给予氯沙坦治疗,观察组采用氯沙坦联合阿托伐他汀治疗,比较两组临床疗效及治疗前后血浆hs-CRP、ET和NO水平变化.结果 观察组有效率为92.86％,显著高于对照组的80.95％（Х^2 =7.85,P＜0.05）;观察组治疗后血浆hs-CRP和ET水平分别为（3.02±0.29） mg/L和（34.44±4.59） μg/L,显著低于治疗前的（5.30±0.38） mg/L和（58.30±5.27） μg/L及对照照组的（4.95±0.36） mg/L和（55.93±5.71） μg/L,差异均有统计学意义（t=7.43、8.10、7.89、8.56,均P＜0.05）;观察组治疗后NO水平为（70.47±4.58） μmol/L,显著高于治疗前的（44.43±3.41） μmol/L和对照组的（46.33±3.81） μmol/L（t=8.69、9.04,均P＜0.05）.结论 氯沙坦联合阿托伐他汀治疗原发性高血压疗效确切,可明显改善患者炎症状态及内皮功能,具有较好的临床应用价值.

Objective To investigate the clinical efficacy of losartan combined with atorvastatin in the treatment of essential hypertension and its influence on the plasma high sensitive C reactive protein（hs-CRP）,endothelin （ET） and the level of nitric oxide（NO）.Methods According to the digital table,84 patients with primary hypertension were randomly divided into the two groups of 42 cases,the control group was given losartan for treatment,the observation group was treated with losartan combined with atorvastatin.The clinical curative effect and the changes of plasma hs-CRP,ET and the level of NO before and after treatment were compared between the two groups.Results The effective rate of the observation group was 92.86%,which was significantly higher than 80.95% of the control group（Х^2 =7.85,P 〈 0.05）;The levels of plasma hs-CRP and ET of the observation group after treatment were （3.02 ± 0.29） mg/L and （34.44 ± 4.59） μg/L,which were significantly lower than （5.30 ± 0.38） mg/L and （58.30 ± 5.27） μg/L of pretreatment and （4.95 ± 0.36） mg/L and （55.93 ± 5.71） μg/L of the control group （t =7.43,8.10,7.89,8.56,all P 〈 0.05）;The NO level of the observation group after treatment was （70.47 ± 4.58）μmol/L,which were significantly higher than （44.43 ± 3.41）μ mol/L of pretreatment and （46.33 ± 3.81） μmol/L of the control group（t =8.69,9.04,all P〈0.05）.Conclusion Atorvastatin combined with losartan has a definite effect in treatment of primary hypertension,which can significantly improve the inflammation and endothelial function of patients that has a good clinical application value.